Angiogenesis Modulating Agents

Agents that modulate the PHYSIOLOGIC ANGIOGENESIS process. This is accomplished by endogenous ANGIOGENIC PROTEINS and a variety of other chemicals and pharmaceutical agents.
DrugDrug NameDrug Indication
DB00102BecaplerminFor topical treatment of skin ulcers (from diabetes)
DB00112BevacizumabAs part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.
DB00480LenalidomideLenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
DB01041ThalidomideFor the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
DB01268SunitinibFor the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.
DB01270RanibizumabFor the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
DB02640FumagillinNot Available
DB04866HalofuginoneFor the treatment of scleroderma, cancer, and restenosis.
DB05088TetrathiomolybdateInvestigated for use/treatment in liver disease and pulmonary fibrosis.
DB05779OglufanideInvestigated for use/treatment in hepatitis (viral, C).
DB06423EndostatinInvestigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
DB06436SemaxanibInvestigated for use/treatment in colorectal cancer and lung cancer.
DB06461SqualamineInvestigated for use/treatment in ovarian cancer, lung cancer, and macular degeneration.
DB08910PomalidomidePomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
DB11366RoquinimexRoquinimex is investigated to be used as a treatment of a number of cancers and autoimmune conditions. As well, roquinimex is researched to be used as adjuvant therapy after bone marrow transplantation in cases of acute leukemia.
DB12056TrebananibNot Available
DB12081AnecortaveNot Available
DB08633TNP-470Not Available
DB06647VolociximabInvestigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
DB11727EndostarNot Available
DB12671BeloranibNot Available
DrugDrug NameTargetType
DB00102BecaplerminPlatelet-derived growth factor receptor betatarget
DB00102BecaplerminPlatelet-derived growth factor receptor alphatarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00112BevacizumabComplement C1r subcomponenttarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabVascular endothelial growth factor Atarget
DB00480LenalidomideProstaglandin G/H synthase 2target
DB00480LenalidomideTumor necrosis factor ligand superfamily member 11target
DB00480LenalidomideProtein cereblontarget
DB00480LenalidomideMultidrug resistance protein 1transporter
DB01041ThalidomideTumor necrosis factortarget
DB01041ThalidomideNuclear factor NF-kappa-B p105 subunittarget
DB01041ThalidomideProstaglandin G/H synthase 2target
DB01041ThalidomideCytochrome P450 2C19enzyme
DB01041ThalidomideCytochrome P450 1A1enzyme
DB01041ThalidomideCytochrome P450 2E1enzyme
DB01041ThalidomideCytochrome P450 2C9enzyme
DB01041ThalidomideProstaglandin G/H synthase 1enzyme
DB01041ThalidomideProstaglandin G/H synthase 2enzyme
DB01041ThalidomideCytochrome P450 3A5enzyme
DB01041ThalidomideFibroblast growth factor receptor 2target
DB01041ThalidomideProtein cereblontarget
DB01041ThalidomideNuclear factor kappa-light-chain-enhancer of activated B cellstarget
DB01041Thalidomidealpha1-acid glycoproteintarget
DB01268SunitinibPlatelet-derived growth factor receptor betatarget
DB01268SunitinibVascular endothelial growth factor receptor 1target
DB01268SunitinibVascular endothelial growth factor receptor 2target
DB01268SunitinibVascular endothelial growth factor receptor 3target
DB01268SunitinibMast/stem cell growth factor receptor Kittarget
DB01268SunitinibReceptor-type tyrosine-protein kinase FLT3target
DB01268SunitinibMacrophage colony-stimulating factor 1 receptortarget
DB01268SunitinibPlatelet-derived growth factor receptor alphatarget
DB01268SunitinibCytochrome P450 3A4enzyme
DB01268SunitinibCytochrome P450 3A5enzyme
DB01268SunitinibCytochrome P450 3A7enzyme
DB01268SunitinibMultidrug resistance-associated protein 4transporter
DB01268SunitinibMultidrug resistance protein 1transporter
DB01268SunitinibCanalicular multispecific organic anion transporter 1transporter
DB01268SunitinibATP-binding cassette sub-family G member 2transporter
DB01270RanibizumabVascular endothelial growth factor Atarget
DB02640FumagillinMethionine aminopeptidase 2target
DB04866HalofuginoneCollagen alpha-1(I) chaintarget
DB04866Halofuginone72 kDa type IV collagenasetarget
DB05088TetrathiomolybdateAmyloid beta A4 proteintarget
DB06423Endostatin72 kDa type IV collagenasetarget
DB06423EndostatinMatrix metalloproteinase-9target
DB06423EndostatinCollagenase 3target
DB06423EndostatinFocal adhesion kinase 1target
DB06423EndostatinCytochrome P450 19A1enzyme
DB06436SemaxanibVascular endothelial growth factor receptor 2target
DB06436SemaxanibProstaglandin G/H synthase 2enzyme
DB08910PomalidomideCytochrome P450 1A2enzyme
DB08910PomalidomideCytochrome P450 3A4enzyme
DB08910PomalidomideMultidrug resistance protein 1transporter
DB08910PomalidomideProtein cereblontarget
DB08910PomalidomideTumor necrosis factortarget
DB08910PomalidomideProstaglandin G/H synthase 2target
DB08633TNP-470Methionine aminopeptidase 2target